Victoza Approved In China: Novo Nordisk Gears Up To Conquer China's Diabetes Market
This article was originally published in PharmAsia News
SHANGHAI - Denmark's Novo Nordisk AS announced March 15 that its human glucagon-like peptide-1 (GLP-1) analogue Victoza (liraglutide) was granted regulatory approval from China's State FDA, and plans to launch the anti-diabetes drug in the second half of this year
You may also be interested in...
China Ramps Up Diagnostics Efforts To Deal With Diabetes Surge; Mandates Screening For At-risk Populations
China will enact regulations to mandate regular screening for diabetes among high-risk populations, which could spur a surge in demand for diabetes treatments and diagnostic devices that dwarfs that of the United States.
In this earnings round up, we zoom in on Merck and Novo Nordisk’s performance in emerging markets for 2012.
In this earnings round up, we zoom in on Merck and Novo Nordisk performance in emerging markets for 2012.